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Purpose: The study aimed to develop a motion capture system that can track, visualize, and
analyze the entire performance of self-injection with the auto-injector.
Methods: Each of nine healthy subjects and 29 rheumatoid arthritic (RA) patients with different degrees of hand disability performed two simulated injections into an injection pad
while six degrees of freedom (DOF) motions of the auto-injector and the injection pad were
captured. We quantitatively measured the performance of the injection by calculating needle
displacement from the motion trajectories. The max, mean, and SD of needle displacement
were analyzed. Assessments of device acceptance and usability were evaluated by a survey
questionnaire and independent observations of compliance with the device instruction for
use (IFU).
Results: A total of 80 simulated injections were performed. Our results showed a similar level
of performance among all the subjects with slightly larger, but not statistically significant,
needle displacement in the RA group. In particular, no significant effects regarding previous
experience in self-injection, grip method, pain in hand, and Cochin score in the RA group were
found to have an impact on the mean needle displacement. Moreover, the analysis of needle
displacement for different durations of injections indicated that most of the subjects reached
their personal maximum displacement in 15 seconds and remained steady or exhibited a small
amount of increase from 15 to 60 seconds. Device acceptance was high for most of the questions (ie, 4; 80%) based on a 0–5-point scale or percentage of acceptance. The overall
compliance with the device IFU was high for the first injection (96.05%) and reached 98.02%
for the second injection.
Conclusion: We demonstrated the feasibility of tracking the motions of injection to measure the
performance of simulated self-injection. The comparisons of needle displacement showed that
even RA patients with severe hand disability could properly perform self-injection with this autoinjector at a similar level with the healthy subjects. Finally, the observed high device acceptance
and compliance with device IFU suggest that the system is convenient and easy to use.
Keywords: subcutaneous injection, auto-injection, motion tracking, hand disability, rheumatoid
arthritis, Cochin score

Introduction
Drug-delivery devices have evolved over the years from traditional syringe systems to
advanced patient-operated drug-delivery devices such as auto-injectors. Studies have
found that auto-injectors are generally viewed as more convenient than traditional
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syringes because they provide a number of benefits, including
a reduced risk of injection site reactions, reduced discomfort,
and greater ease of use.1,2 Prefilled, disposable auto-injectors
have the advantage of simplicity, as they automatically insert
the needle and deliver a controlled dose of drug into the skin
while requiring minimal training for patients. Despite these
advances, patients with reduced manual dexterity (such as
rheumatoid arthritic [RA] patients) or other deficiencies
may experience complications following correct procedures
with these auto-injection devices. Thus, it is desired to analyze more carefully the way users manipulate and use the
auto-injector.
Previous research on auto-injectors was primarily focused
on the evaluation of the device acceptance and usability.
Device acceptance is concerned with the device’s ease of
use, safety, and patients’ willingness to adopt the device.
The methods to assess the device acceptance were mostly
based on survey questionnaires reported by participants3–6 or
collected from physicians or nurses.7–9 The device usability,
which is patients’ compliance with device instruction for
use (IFU), was evaluated by independent observers who
monitored patients’ handling of the auto-injector system
during injections.10,11
Besides device acceptance and usability, capturing and
analyzing the performance of self-injection with auto-injectors
is essential in acquiring precise data concerning the procedure
and also in quantifying the performance. In Berteau et al’s12
study, accuracy and consistency of the injected volume,
skin reaction, pain, and fluid depot in the hypodermis layer
were quantitatively measured by gravimetric methodology,
visual analog scale, and ultrasound sonography, respectively.
Since the perceived pain on injection site may cause negative
effects on acceptance and adherence to treatment in patients
with chronic diseases, auto-injectors with different needle
lengths were analyzed to minimize the injection pain.13
Moreover, motion capture systems have previously been
used in many medical applications for quantitative assessment of surgical skills and dexterity during laryngoscopic,
arthroscopic, and open procedures.14,15 Motions were captured
by electromagnetic sensors,16 infrared cameras,17 or Kinect®
sensors.18 These methods all have advantages in terms of
objectively recording, analyzing, and visualizing motion
data. However, to the best of our knowledge, no studies
have been performed for evaluating motion capture data in
injection-related procedures.
In this study, our objective was to show that motion
analysis could contribute to evaluate subjects’ performances
of self-injection with auto-injector. The performances of
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subjects were quantified by calculating the needle displacement during the simulated injection. Comparisons were
made between healthy and RA subjects. In addition, device
acceptance and usability were also assessed in this study.

Methods
Study design and setting
This study was conducted in the research suite at Shugoll
Research, Bethesda, MD, USA. The suite consists of an
interview room and a viewing room. All injections were
performed in the interview room while independent observations were made in the viewing room. A total of 38 subjects
were recruited in the study, including nine healthy volunteers
and 29 RA patients with different levels of hand dysfunction. The research protocol was approved by an internal
committee from the Patient Safety Organization, Quality
Organization, Regulatory Organization, and Development
Organization at MedImmune and complies with principles
expressed in the Declaration of Helsinki. According to the
guide that was published by Ximedica, an independent and
industry leader in human factors research, we assessed the
risk of this study to participants to be low. At this risk level,
Institutional Review Board approval was officially waived
by MedImmune. Written informed consent was obtained
from the participants.
Each subject was asked to perform two simulated subcutaneous self-injection using a foam pad attached to the
most common injection sites (one on the thigh, the other on
the abdomen) in random order. As an exploratory objective
to increase the difficulty of injection, we also randomly
selected four healthy subjects to perform an extra injection
while wearing gloves specifically designed to limit hand
dexterity. Two observers were present in this study and
directly observed all activities. In order to standardize the
observations, the observers used a written guide as a reference to record the same set of information for all the subjects
(Table 1). The interview room simulated the environment
that would normally be encountered in the subjects’ homes
or other appropriate environments. We also videotaped all
performances with an external video camera.
To capture the performances of injections, we used the
3D Guidance trakSTAR® electromagnetic motion capture
system (Ascension Technology Corporation, Shelburne, VT,
USA) to continuously track the positions and orientations of
the injector and the injection pad (Figure 1). One sensor was
attached to the top of the injector (to avoid physical interference with the subject’s hand). Another was attached to the
side of the injection pad. The transmitter with an operating
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Table 1 Observation steps
Category

Steps

Injection(s)

Injection
procedure

S1. Grasp device relative to injection
site with one hand
S2. Use the other hand to remove cap
S3. Make sure that the viewing window
is in your line of sight
S4. Position the device at a 90° angle
against the skin of the injection site
S5. Push auto-injector against the
injection site until start click occurs
S6. Monitor injection progress and wait
for end of injection
S7. Hold the device in place for at least
60 seconds
S8. Remove auto-injector from
injection site in a perpendicular position

Injections
1 and 2

Figure 2 Virtual fiducials used for calibration.

range of ~1 m diameter hemisphere was placed in a fixed
position and was used as a coordinate reference. We eliminated any magnetic materials in the interview room to assure
the accuracy of the position sensors. All the sensor cords
were organized in order not to block the view of subjects or
interfere with their motions. The auto-injector is a typical
prototype of many commercially available devices.
Six degrees of freedom (DOF) motions of the injector and
the injection pad were recorded at 60 Hz during injections. A
calibration procedure was performed before the experiment
by using a 1.5 mm cylindrical sensor from the same motion
capture system. We used its tip to measure specific x, y, and
z positions on the injector and the injection pad. Two points
were selected on the injector, including the top center of
the injector and the needle tip of the injector (yellow dots
in Figure 2). To determine the motion of the injector with
respect to the injection pad, three additional points were

7UDQVPLWWHU

3RVLWLRQVHQVRUV
,QMHFWLRQ
SDG

$XWRLQMHFWRU
Figure 1 Experimental setup with the injection device.
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selected at each corner of the injection pad. The local coordinate system of the injection pad was defined by these three
points, which were sufficient to define an origin and the x-,
y-, and z-axes. The z-axis was defined as the vector that was
perpendicular to the injection pad. The x–y plane was defined
as the pad surface. Given the positions of the two sensors that
we attached to the injector and the injection pad, we could
further calculate the positions of the five selected points. The
motion capture system was connected to a personal computer
through a universal series bus (USB) port. Data acquisition,
analysis, and 3D visualization of the data were implemented
using software developed in our laboratory.
The study started with the RA subjects filling out the
Cochin scale,19 a practical instrument for rating hand disability in RA patients. It comprised 18 questions on daily activities, each scored from 0 (without difficulty) to 5 (impossible
to do). A total score obtained by simply adding the scores of
the 18 questions would reflect each patient’s hand function
severity, with a higher score representing more severe hand
dysfunction. Other information, such as gender, previous
self-injection experience, and pain severity in hands (only for
RA subjects, scored from 0 [no pain] to 5 [severe pain]), was
also reported by all the subjects. The interviewer gave each
subject instructions on how to properly use the device before
the first injection. All the subjects were asked to hold the
injector in place for 60 seconds while seated in a chair even
though the time for a full dose is typically ~10 seconds. This
was done in order to analyze the motion for extended injections. During each injection, the motion data were streamed
and exported to the computer for further analysis. An eightstep injection checklist was used to help the observers record
subjects’ noncompliance with the injection procedure, including errors when subjects handling the auto-injector and performing the injection (Table 1). After the injection, a survey
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questionnaire containing 12 questions was used to assess
the device acceptance (Table 2). To evaluate the perceived
ease and confidence of using the device, subjects completed
the first four questions (Q1–Q4) after both injections. At the
end of the second injection, eight more questions (Q5–Q8)
were administered concerning the overall experience of the
injection process and the device design.

Data analysis
Data were analyzed using software developed in-house,
Matlab® (Mathworks, Natick, MA, USA) and JMP® Version 12

(SAS Institute Inc., Cary, NC, USA). The performance of
injection, device acceptance, and usability were evaluated
based on the motion we collected from the motion capture
system and the survey questionnaires correspondingly.

Measurement of the injection performance
Human skin has been demonstrated to have elastic properties
and is subject to the mechanical laws defining its properties.20
In the elastic range, the property is expressed by Young’s
modulus: E=σ/ε, where σ is defined as stress and ε is defined
as strain. In addition, σ=F/A, where F is the applied force and

Table 2 Survey questionnaire
Category

Questions

Responses

Injection(s)

Injection evaluation

Q1. On a scale of 1–5, where 1 is not at all
confident and 5 is very confident, please rate
how confident you are that you administered
the injection successfully?
Q2. On a scale of 1–5, where 1 is very
difficult and 5 is very easy, how would you
rate the ease of performing an injection?
Q3. Was there anything about the injection
process that caused you to be concerned or
to hesitate or that made you feel like you
were just about to make a mistake?
Q4. Imagine a time in the past when the
arthritis in your hands has been exceptionally
painful. Do you think you would have been
able to perform the injection if you had been
feeling that way today?
Q5. On a scale of 1–5, where 1 is very
difficult and 5 is very easy, how easy was it
to remove the cap of the auto-injector?
Q5.a. In your opinion, was this amount
of ease to remove the cap acceptable or
unacceptable?
Q6. On a scale of 1–5, where 1 is very
difficult and 5 is very easy, how easy was it
to press down on the auto-injector?
Q6.a. In your opinion, was this amount of
ease to press down on the auto-injector in
place acceptable or unacceptable?
Q7. On a scare of 1–5, where 1 is very
difficult and 5 is very easy, how easy was it
to hold the auto-injector in place for the
duration of the injection?
Q7.a. In your opinion, was this amount
of ease to hold the auto-injector in place
acceptable or unacceptable?
Q8. On a scale of 1–5, where 1 is very
difficult and 5 is very easy, how easy was it
to grip the auto-injector?
Q8.a. In your opinion, was this amount of
ease to grip the auto-injector acceptable or
unacceptable?

Scale from 1 (not at all
confident) to 5 (very confident)

Injections
1 and 2

Auto-injector experience

Scale from 1 (very difficult) to
5 (very easy)
Yes/no

Yes/no

Injections
1 and 2
(RA only)

Scale from 1 (very difficult) to
5 (very easy)

Injection 2

Acceptable/unacceptable

Scale from 1 (very difficult) to
5 (very easy)
Acceptable/unacceptable

Scale from 1 (very difficult) to
5 (very easy)

Acceptable/unacceptable

Scale from 1 (very difficult) to
5 (very easy)
Acceptable/unacceptable

Abbreviation: RA, rheumatoid arthritics.
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A is the original cross sectional area and ε=∆l/l, where ∆l is
the change in length and l is the original length. Therefore,
the change in length of the skin (∆l/l) is proportional to the
force (F) applied to it. In our study, we used needle displacement as an indication of the amount of force that the subject
applied to the injector in the direction of the displacement.
Considering that there is no known maximum acceptable
force on the injection point and that limit may vary from
one subject to another depending on age, anatomic locations,
and other factors, this analysis was mainly for measuring the
relative forces applied on the skin by the subjects.
In order to calculate the needle displacement, two
points were defined on the needle of the injector: tip point
and entry point. The tip point was defined as the tip of the
needle. The entry point was defined as the intersection of
the needle with the pad surface (Figure 3). In this particular
device, when injection starts, instead of the needle moving
forward, the plastic shield (orange part in Figure 3) retracts
and stops when the safety mechanism clicks. The exposed
part of the needle is 6 mm, which is the distance from the
entry point to the tip point. We make the assumption that
movements in the direction parallel to the needle cause very
little stretch or compression to the skin since there is very

little friction between the needle and the skin. The relevant
needle displacement can be measured by the displacements
of the entry and tip points.
For our study, we analyzed the motion within the duration
of the injection, which was defined as the time (in seconds)
from when the needle of the injector was fully inserted
into the injection pad until the timer rang (60 seconds). We
extracted the segment of the duration of injection from the
motion trajectory and set the first needle pose as the initial
pose (Figure 4). Then, we calculated the displacement of
the entry point de and the displacement of the tip point dt
with respect to the initial pose for all subsequent needle
poses during the 60 seconds’ injection. Figure 4 illustrates
the calculation of needle displacement between the initial
needle pose and one of the subsequent needle poses. We first
transformed the entry/tip points of both the initial needle pose
(pe, pt) and the current needle pose (pe′, pt′) to the local coordinate system of the injection pad to determine the motion of
the needle with respect to the injection pad. Then, we moved
the current needle pose in the direction of its needle pose
to the same level as the pad surface at the initial needle pose.
The resulting pose was the adjusted needle pose (pe″, pt″).
Finally, the displacements of the entry point de and the tip
point dt were calculated as the Euclidean distance between
the initial and the adjusted needle poses.
By knowing the displacements of the entry point and the
tip point for each pose during the injection, we determined
a time series trajectories of needle displacements for each
injection. Comparisons regarding max, mean, and SD of
needle displacement in 60 seconds’ injection were made
between the healthy group and the RA group on both thigh
and abdomen data. A nonparametric test, Wilcoxon rank
sum, was used to analyze the mean difference in each comparison. Subgroup analyses of the mean needle displacement
,QLWLDOSRVH
&XUUHQWSRVH

3DGVXUIDFH
GH
1HHGOHVKLHOG

S″
H

SH

S′H
PP

(QWU\SRLQW

S″W

GW

SW

S′W
7LSSRLQW
Figure 3 The state of the auto-injector when fully inserted into skin.
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Figure 4 An illustration for calculating the needle displacements of the entry point
and the tip point (de, dt) from the initial pose (pe, pt) to the adjusted current pose
(pe″, pt″ ). (pe′, pt′ ) is the original current pose.
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in the RA group were carried out based on gender, previous
experience in self-injection, grip method, injection site, pain
in hand, and Cochin score. Generalized estimating equation
was used to account for the repeated measures. Analyses
of needle displacements for different durations of injection
were also carried out to determine if the subjects could hold
the injector in place for an extended time (ie, 15, 30, 45, and
60 seconds).

Evaluation of the device acceptance and usability
The device acceptance was evaluated based on the results of
the survey questionnaire. We computed mean score (±SD)
for the 5-point Likert scale questions (Q1, Q2, Q5, Q6,
Q7, and Q8) and percentage of acceptance for the binary
questions (Q5.a, Q6.a, Q7.a, and Q8.a). For question Q3,
we counted the percentage of subjects who felt they had
not made a mistake. For question Q4, we calculated the
percentage of subjects who thought they would be able to
perform the injection even when arthritis in their hands was
exceptionally painful. A score of 4 or a percentage of 80
was considered as high acceptance.
The device usability was evaluated by the observers who
monitored the handling of the auto-injector and recorded
each error that occurred during execution of the injection
steps. The IFU compliance was assessed by analyzing the
percentage of injections where all steps were correctly
performed. An overall mean percentage was calculated

for the first injection and the second injection. The mean
percentage in the RA group was calculated. A percentage
of 80 was considered acceptable.

Results and discussion
All 38 subjects, including nine healthy volunteers and
29 subjects with RA, were analyzed in our study. Among the
RA subjects, 19 subjects had experiences with self-injection
(using a needle and syringe and/or an auto-injector) prior to
inclusion in the study while 10 subjects had no experience.
All of the RA subjects had Cochin scores 70, of whom
17 subjects had mild hand disability (30) and 12 subjects
had severe hand disability. Motion data were collected for all
of the subjects, with the injection procedure being performed
twice on a different injection site for each subject. A total
of 76 data sets with four additional attempts with dexteritylimiting gloves were analyzed.

Comparisons of needle displacement
The max, mean, and SD of needle displacement of each injection attempt were plotted separately (Figures 5–7). In each
boxplot, we compared the needle displacement between the
healthy group and the RA group based on thigh and abdomen
measurements. The actual data values are shown as yellow
dots, spreading out laterally to avoid overlap. The body of the
box extends from the 25th percentile to the 75th percentile of
the data (so half the points fall within the box) with a thick
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Figure 5 Comparison of max needle displacement between the healthy group and the RA group based on thigh and abdomen measurements.
Abbreviation: RA, rheumatoid arthritics.
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Figure 6 Comparison of mean needle displacement between the healthy group and the RA group based on thigh and abdomen measurements.
Abbreviation: RA, rheumatoid arthritics.

line marking the median. The whiskers that extend on either
side of the box represent a region that should contain most
of the points. In our analysis, the maximum whisker length
was set to 1.5. Points beyond the whiskers are considered
outliers (±2.7 SD).
For the max and mean needle displacement, clear differences were found on both thigh and abdomen measurements,

with higher medians in the RA group. This indicated that
subjects in the RA group had a higher needle deflection than
the healthy group. However, the differences did not reach
statistical significance (P=0.074 for thigh max and P=0.918
for abdomen max; P=0.257 for thigh mean and P=0.81 for
abdomen mean). A significant difference was not found in
the SD between the healthy group and the RA group (P=0.45
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Figure 7 Comparison of SD of needle displacement between the healthy group and the RA group based on thigh and abdomen measurements.
Abbreviation: RA, rheumatoid arthritics.
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Figure 8 Comparison of mean needle displacements between subgroups in
RA subjects.
Abbreviation: RA, rheumatoid arthritics.
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for thigh SD and P=0.257 for abdomen SD). Across all the
comparisons, we notice that the range of values is larger for
abdomen measurement than for thigh measurement, which
indicates that the subjects had more difficulty keeping the
injector angled correct (as reflected in the max/mean of
needle displacement) and steady (as reflected in the SD of
needle displacement) on the abdomen.
The subgroup analyses of the average needle displacement based on gender, previous experience in self-injection,
grip method, injection site, pain in hand, and Cochin score
were performed (Figure 8). The results showed significant
differences between the subgroups regarding gender and
injection site. Specifically, the male group had larger needle
displacement than the female group (P=0.002). However, this
effect was not clinically significant. Injections performed on
abdomen had larger needle displacement than the injections
performed on thigh (P=0.025). This result was in accord with
previous comparisons on the needle displacement between
the healthy group and the RA group, which shows that it is
more challenging for subjects to perform injections on the
abdomen than on the thigh. There were no statistically significant differences between the rests of the subgroups (P0.05).
In particular, the Cochin score had no significant impact on
the performance of injection (P=0.249), which means that the
degree of hand disability is not an indication of deteriorated
self-injection capability with the auto-injector.
Figure 9 illustrates the comparison of mean needle
displacements between healthy volunteers who performed
extra injections by wearing dexterity-limiting gloves and
RA subjects. We also included the average needle displacement of these healthy volunteers’ previous two injections
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Figure 9 Comparison of mean needle displacement with or without gloves.
Abbreviation: RA, rheumatoid arthritics.

as a reference. We can conclude that injection with gloves
did limit hand dexterity and lead to deteriorated injection
performance (larger needle displacement).
The needle displacements for different durations of injection were also analyzed to determine the performance for
longer injections. As there is no known maximum acceptable
displacement and that limit may vary from one subject to
another, this analysis was used to compare the performance
of different populations. The needle displacement at every
1/60 seconds for each subject is presented in Figure 10.
We observed that there was no major difference between the
healthy and the RA subjects. We then analyzed both groups
together. Considering the complexity of the data, we did not fit a
statistical model. Therefore, the analysis was done on the maximum displacement reached at every time point (Figure 11).
We calculated the proportion of subjects that reached
their maximum displacement at 15 seconds, as well as the
proportion of subjects that reached the 50th, 75th, 90th, and
95th percentile of their displacement at 15 seconds (Table 3).
The results showed that ~60% of the subjects reached
the 90th percentile of their personal displacement within
the first 15 seconds. To determine if the displacement would
significantly increase 15 seconds, we observed the maximum displacement reached within the first 15, 30, 45, and
60 seconds of the injection (Figure 12). The results indicated
that most subjects’ displacement at 60 seconds was almost
the same as the displacement that they reached at 15 seconds.
Except in some rare cases, the increase of the displacement
after 15 seconds was quite small.
The above analysis shows that increasing the duration of
the injection above 15 seconds did not significantly affect
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Figure 10 Needle displacement at every 1/60 second for each subject, split by injection site.
Notes: Black curves represent healthy subjects, and colored curves represent RA subjects. The color scale (blue to red) indicates the severity of the disease (low to high).
Abbreviation: RA, rheumatoid arthritics.

Device acceptance and usability

the maximum needle displacement. However, caution needs
to be applied in the interpretation of the results. Because of
the complexity of the data, no statistical inference had been
performed. Also, since the subjects injected the needle in the
pad, pain was not a factor.
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The mean scores (±SD)/percentages of all the survey questions
were calculated for both all the subjects and the subjects in
the RA group (Tables 4 and 5). Device acceptance was high
for most of the questions (ie, 4; 80%) except Q3 and Q5


































6HFRQG
Figure 11 Maximum distance reached up to time t.
Notes: The vertical line is t=15 seconds. Blue curves represent healthy subjects, and red curves represent RA subjects.
Abbreviation: RA, rheumatoid arthritics.
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Table 3 Percentage of subjects who reached a given percentile of their distance at 15 seconds
Injection
site

50th
percentile

75th
percentile

90th
percentile

95th
percentile

100th percentile
(maximum)

Abdomen
Thigh

89.19%
83.78%

78.38%
67.57%

59.50%
62.16%

56.76%
56.76%

32.43%
29.73%

(ie, 3; 68%). Q3 was related to the probability of the
subjects feeling like they would make a mistake. As reported
by the subjects, some felt like they made a mistake because
they could not decide whether the correct dose was given or
whether a dose had been given at all. This was because they
failed to monitor the viewing window on the injector, which
indicated the volume of the dose. However, the percentage for
Q3 increased after second injection, which indicated that fewer
subjects made mistakes compared to the first injection. Q5 was
about the difficulty of removing the cap of the injector. Most
subjects complained that it required a lot of force to remove
the cap, especially those RA subjects who had severe hand disability. However, when they were asked whether this amount
of force to remove the cap was acceptable or not (Q5.a), a high
acceptance (86.84% for overall, 82.76% for RA subjects) was
achieved because they thought the amount of force to open
the cap is necessary due to safety considerations.
Device usability was also evaluated based on the percentage of injections where all steps were correctly performed

Conclusion
In this study, we developed the first, to the best of our knowledge, motion analysis system to objectively measure simulated self-injection with an auto-injector. We demonstrated
the feasibility of tracking the motions of injection to compare
the performances between healthy and RA subjects. The
quantitative analysis of needle displacement showed a similar
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for both the first injection and the second injection. The
mean percentage of correctly executed steps for the overall
subjects was 96.05% for the first injection and 98.02% for the
second injection. In the RA group, the corresponding mean
percentages were 95.69 and 98.71. We can find that after
second injection, a higher usability was achieved than the first
injection both for all the subjects and the RA subjects, which
may have been due to greater familiarity with the device.
According to the notes made by the observers, the step that
the subjects failed most frequently was placing the viewing
window in their line of sight (S3 in Table 1).
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Figure 12 Maximum distance reached at 15, 30, 45, and 60 seconds per subject.
Note: Healthy subjects are on the left and RA subjects on the right.
Abbreviation: RA, rheumatoid arthritics.
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Table 4 Overall device acceptance
Questions
Q1
Q2
Q3
Q4
Q5
Q5.a
Q6
Q6.a
Q7
Q7.a
Q8
Q8.a

Mean (±SD)/percentage
Injection 1

Injection 2

4.53 (±0.92)
4.70 (±0.56)
73.68%
RA only

4.76 (±0.59)
4.68 (±0.62)
81.58%
3.84 (±1.05)
86.84%
4.76 (±0.49)
97.37%
4.29 (±0.96)
89.47%
4.59 (±0.77)
94.74%

Abbreviation: RA, rheumatoid arthritics.

Table 5 Device acceptance in RA group

Q1
Q2
Q3
Q4
Q5
Q5.a
Q6
Q6.a
Q7
Q7.a
Q8
Q8.a

Mean (±SD)/percentage
Injection 1

Injection 2

4.48 (±0.91)
4.62 (±0.62)
68.97%
82.75%

4.72 (±0.65)
4.62 (±0.68)
79.31%
89.66%
3.90 (±1.05)
82.76%
4.76 (±0.51)
96.55%
4.21 (±1.02)
86.21%
4.50 (±0.85)
93.10%

Abbreviation: RA, rheumatoid arthritics.
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level of performance among all the subjects with slightly
larger, but not statistically significant, needle displacement
in the RA group. Subgroup analyses showed that previous
experience in self-injection, grip method, pain in hand, and
Cochin score did not have significant effects on the performance of injection. The analysis of needle displacement in
different durations of injection showed that most subjects
could hold the injector in place without significant increase of
displacement from 15 to 60 seconds. However, caution needs
to be applied in interpreting the results because the injection was performed in an injection pad and not actual skin.
Finally, the observed high device acceptance and percentage
of successfully handling the auto-injector (in compliance
with the IFU) suggest that the system is convenient and easy
to use. However, one limitation of this study was the small
sample size, especially the size of the healthy group, which

Questions

may reduce the stability of the factor analysis and limit the
interpretation of the results. The small sample size and the
observational nature of the statistical analysis mean that
the P-values reported in this study should be used to guide
interpretation rather than being definitive answers.
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